Clinical Trial

Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis

Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and identify the biomarkers of typing, and to explore the clinical outcomes of different inflammatory phenotypes.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-18.
Trial Details
NCT Number NCT07040332
Lead Sponsor Qianfoshan Hospital
Collaborators: Shanghai Pulmonary Hospital, Shanghai, China, Fudan University, Guizhou Provincial People's Hospital, The First Hospital of Jilin University, Qilu Hospital of Shandong University
Conditions Allergic Bronchopulmonary Aspergillosis (ABPA)
Enrollment 140 participants
Start Date 2025-05-10
Primary Completion 2027-07-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-04